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The determination of final organ size is a highly coordi-
nated and complex process that relies on the precise regu-
lation of cell number and/or cell size. Perturbation of organ
size control contributes to many human diseases,
including hypertrophy, degenerative diseases, and cancer.
Hippo and TOR are among the key signaling pathways
involved in the regulation of organ size through their
respective functions in the regulation of cell number and
cell size. Here, we review the general mechanisms that
regulate organ growth, describe how Hippo and TOR
control key aspects of growth, and discuss recent findings
that highlight a possible coordination between Hippo and
TOR in organ size regulation.
Introduction
Precise control of organ size is a key feature of metazoans
and a crucial process during animal development and regen-
eration. Classical organ transplantation studies provided
the first clues that both intrinsic and extrinsic mechanisms
operate in organ size control. For instance, transplantation
of multiple fetal thymus glands into a developing mouse
results in each thymus gland growing to its characteristic
adult size, suggesting an organ-autonomous mechanism
for size control [1]. Similarly, Drosophila imaginal discs
grown outside their environment attain a normal size even
if given additional time to grow, suggesting that growth
determinants residing within the imaginal discs provide
autonomous growth cues [2]. In contrast, transplantation of
multiple spleens into a developing mouse results in the
spleens collectively attaining the mass of one adult spleen,
indicating a non-autonomous mechanism for organ size
regulation [3].
Regeneration studies also revealed both intrinsic and
extrinsic mechanisms for the regulation of organ size. For
instance, Drosophila imaginal discs or the mammalian liver
can regenerate to their original size following removal of
part of their mass [4,5], implying that some form of memory
is retained in these organs. In contrast, the intestine is inca-
pable of recovering its length following resection, despite the
remarkable self-renewal capacity of its stem cells [6]. These
studies indicate that the ability to recover size and function
following injury varies between organs.
In many cases, the regulation of organ size is achieved by
systemic or ‘extrinsic’ factors, which can exert either positive
or negative effects on size. In Drosophila and mammals, the
rate of growth and final organ size of developing organs are
dependent on nutritional status and are controlled by circu-
lating factors, like growth hormone, insulin, and insulin-like
growth factor (IGF). In the blood and central nervous system,
final organ size is determined primarily by growth factors
through the regulation of cell proliferation and apoptosis.Department of Pharmacology and Sanford Consortium for
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regulation by growth factors, is the critical determinant of
organ size, as shown by studies using genetic methods for
altering the number of organ-specific progenitor cells during
early embryonic development. For instance, the final size of
a pancreas from a primordium with a reduced number of
progenitor cells is small whereas that of the liver is normal,
suggesting that final pancreas size is controlled by an
intrinsic program established early in development that is
not subject to growth compensation, whereas final liver
size is not limited by reductions in the progenitor cell number
[7]. Thus, embryonic progenitor cells may represent a crucial
and limiting determinant of some but not all organs.
In this review, we discuss the contributions of cell death,
proliferation and growth to the regulation of organ size,
and then focus on the roles of the highly conserved Hippo
and target of rapamycin (TOR) signaling pathways in organ
size control.
Regulation of Organ Size
Organ growth is a consequence of increased cell number,
cell size, or both (Figure 1). In general, cell number is depen-
dent on the balance between cell proliferation and cell death,
whereas cell size is dependent on cell growth.
Role of Cell Proliferation
Cell proliferation is controlled by extracellular mitogens and
inhibitory molecules to ensure that cell division takes place
only when more cells are needed. Mitogenic signals, such
as epidermal growth factor (EGF), activate intracellular
signaling pathways to promote DNA replication and cell-
cycle progression [8]. Conversely, inhibitory molecules acti-
vate intracellular signaling pathways to block cell-cycle
progression and arrest cells in G1 [9]. A family of kinases
called cyclin-dependent kinases (CDKs) are cyclically acti-
vated to trigger the different phases of the cell cycle, and
various cell-cycle checkpoints exist to ensure proper
progression [10]. Therefore, cell proliferation signals impinge
on CDK activity to control cell division.
An important role of cell proliferation in organ size control
is highlighted in transgenic mouse studies. One important
regulator of the cell cycle is the p27 gene, which inhibits
cyclin–CDK complexes and arrests cells at G1 in response
to transforming growth factor b, cell-contact inhibition, and
serum deprivation in epithelial cell lines [11]. Mice deficient
in p27 have enlarged organs due to increased proliferation
rather than decreased cell death or increased cell size
[12–14], indicating a critical role of a cell-cycle regulator in
proliferation and organ size control. However, it should be
noted that overexpression or loss-of-function of most cell-
cycle regulators has no effect on organ size, indicating that
the cell-cycle machinery may not be the key determinant
for organ size regulation.
A role of cell proliferation in organ size control is also
demonstrated in transgenic mice in which stabilized b-cate-
nin is overexpressed in neural precursors [15]. These mice
have enlarged brains with an increased number of neural
precursors. A detailed analysis of these cells reveals that
they do not differentiate and are in a proliferative state,
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Figure 1. The TOR and Hippo pathways in
organ size control.
TOR regulates organ size by stimulating cell
growth, thereby increasing cell size. Hippo
controls organ size by restricting cell number
via inhibition of proliferation and induction of
apoptosis.
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cycle exit and cell differentiation may
serve as important mechanisms for
the regulation of cell proliferation and
organ growth. It should be noted that,
while cell proliferation clearly plays an
important role in organ size control,
only a few of the many genes that regu-
late proliferation have critical functions
in organ size control. Thus, the mainte-
nance of organ size is a much more
complex process that requires addi-
tional inputs and factors beyond cell
proliferation.
Role of Cell Death
Apoptosis is a major form of cell death
that controls cell number during animal
development. Studies in Drosophila indicate that apoptosis
is required to attain appropriate wing size during develop-
ment [16]. This apoptosis-dependent regulation of wing
size is achieved via induction of the pro-apoptotic gene
hid by the growth regulator dMyc [16], suggesting that
modulation of dMyc levels is a mechanism for the regulation
of organ size during development. Studies in mammals
also confirm a role of apoptosis in organ size control. For
example, transgenic mice heterozygous for the gene Pax2
develop kidneys that are considerably smaller than wild-
type mice, as a result of increased apoptosis of duct
epithelial cells rather than decreased proliferation [17].
Similarly, mutations of the Drosophila homolog of Pax2
result in apoptosis of photoreceptors in the eyes and
impair eye development [18], indicating a functional conser-
vation of Pax2 in the regulation of apoptosis and organ size.
Thus, in some cases apoptosis is a critical determinant of
organ size.
Apoptosis is initiated in response to developmental cues,
environmental insults, or a lack of survival factors. Survival
factors induce the expression of genes that are important
for the suppression of apoptosis, such as the inhibitor of
apoptosis (IAP) and members of the Bcl-2 family of proteins.
Overexpression of the anti-apoptotic gene bcl2 in mice has
been shown to result in enlarged brains with increased
numbers of neurons [19–21]. In contrast, overexpression of
the pro-apoptotic gene p53 in mice results in smaller kidneys
[22]. Many growth factors provide key survival signals for
their respective target cells via activation of the phosphoino-
sitide 3-kinase (PI3K) pathway, whereby the downstream
target AKT suppresses activation of components of the cell
death machinery.
Apoptosis is also induced by signals between cells.
Genetic mosaic studies in Drosophila have uncovered a
phenomenon called cell competition, in which cells that are
otherwise viable get eliminated if their neighboring cellshave a growth advantage, as a mechanism for organ size
control [16]. For instance, slowly growing cells are eliminated
when they are next to cells that grow at a normal rate [23].
Analysis of known signaling pathways has implicated the
bone morphogenetic protein (BMP) family member Decap-
entaplegic (Dpp) and the Jun N-terminal kinase (JNK)
pathway in cell competition. More recently, the Hippo
pathway has been shown to play a role in cell competition
through regulation of dMyc via Yorkie [24,25], with higher
dMyc levels providing a competitive advantage.
Coordination of Cell Proliferation andCell Death inOrgan
Size Control
Control of cell number is dependent on a balance between
cell proliferation and cell death. As such, cell proliferation
and cell death must be tightly regulated to maintain organ
size. This coordination is particularly important during the
process of regeneration, when both inducers of proliferation
and inhibitors of apoptosis must be coordinately activated to
support organ growth. Several tumor suppressor genes
involved in organ size control through regulation of prolifer-
ation and apoptosis have been identified using genetic
mosaic screens, including components of the recently
discovered Hippo signaling pathway, which will be dis-
cussed in detail later in the review.
Role of Cell Growth
Cell growth is initiated in response to a myriad of signals,
such as extracellular growth factors and nutrient sufficiency.
Growth factors bind to cell surface receptors and activate
intracellular signaling pathways that ultimately lead to
increased protein synthesis and decreased protein degrada-
tion. Pioneering studies in Drosophila suggested that inhibi-
tion of the translation of a subset ofmRNAs throughmutation
of the Drosophila ribosomal protein p70 S6 kinase (DS6K)
alters growth rates, as well as cell and organ size [26].
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Figure 2. The Hippo pathway in Drosophila
and mammals.
Corresponding genes in (A)Drosophila and (B)
mammals are shown. Core components,
upstream regulators, and downstream targets
of the Hippo pathway are labeled in blue, pink,
and green boxes, respectively. See text for
details.
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smaller cells. However, the cell numbers are not significantly
changed when compared with the wild-type flies, indicating
that cell size, not cell number, accounted for the size change.
Central to the regulation of cell size is the TOR kinase, which
activates DS6K. InDrosophila,mutations in TOR inhibit larval
growth, and this phenotype can be rescued by DS6K overex-
pression [27]. Another major regulator of growth is the Myc
transcription factor [16,28]. Myc induces several genes
involved in ribosome biogenesis and protein synthesis,
including the eukaryotic translation initiation factors eIF4E
and eIF2a [29,30], which are necessary for growth. In
mammals overexpression of Myc results in increased liver
size characterized by enlarged hepatocyte size [31]. It should
be noted that, although changes in cell size can have signif-
icant effects on organ size, changes in cell number more
often account for organ size differences and that, in several
cases, modulation of cell growth does not influence organ
size (reviewed in [32]).
Coordination of Cell Number and Cell Size
Organ growth is often associated with increases in both
cell number and cell size. This was recognized with the
identification of the gene encoding Chico, a Drosophila
insulin receptor substrate (IRS) protein. Flies mutant for
Chico are small with reduced cell size and cell number [33],
providing evidence for the role of the IGF pathway in imaginal
disc growth control. Acting downstream of Chico, the
Drosophila class 1A PI3K Dp110 and its adaptor p60 were
also shown to regulate imaginal disc cell size, cell number,
and organ size. Mutations ofDp110 and p60 in mitotic clones
reduced cell size and cell number, while overexpression of
Dp110 increasedwing disc size and caused cells to accumu-
late in G2 phase [34]. Moreover, expression of Dp110 in one
compartment of the wing imaginal disc increased not only
the size of the compartment but also the size of the disc, indi-
cating that Dp110 activation is sufficient for imaginal disc
growth. Two prominent downstream targets of Dp110 aredAKT and dTOR. The PI3K pathway
thus coordinately regulates cell number
and cell size to promote organ growth.
Coordination of cell number and cell
size in organ size control is also sup-
ported by studies on the gene myosta-
tin, wherein mice with myostatin
deletion are larger than wild-type mice
and have bigger muscles due to




First elucidated in Drosophila, the
Hippo pathway consists of the tumorsuppressor genes Warts (wts), Salvador (sav), Hippo (hpo),
and Mob as tumor suppressor (mats) (Figure 2), mutations
of which lead to massive tissue overgrowth. wts encodes
a member of the nuclear Dbf2-related (NDR) kinase family
[36,37]. Loss of wts leads to robust cell-autonomous over-
growth in various epithelial structures such as the wings,
the legs, and the eyes. sav encodes a WW-domain-contain-
ing protein. Mutation of sav results in a similar, although
weaker, cell-autonomous overgrowth to that observed in
wts mutant cones [38,39]. Additionally, loss of wts or sav
results in increased proliferation and diminished apoptosis,
indicating that wts and sav coordinately regulate both of
these cellular processes to control cell number. hpo, from
which the pathway name was derived, encodes a Ste20
family protein kinase. hpo exhibits a similar loss-of-function
overgrowth phenotype to that reported for sav orwts. In vitro
and cell culture-based studies reveal that Hpo phosphory-
lates and activates Wts, and that Sav potentiates this phos-
phorylation [40]. Mats, a protein of theMob1 family, interacts
with Wts and potentiates the intrinsic kinase activity of Wts
[41] as well as Hippo-mediated growth [42]. Consistently,
loss of mats function results in increased cell proliferation,
reduced apoptosis, and induction of tissue overgrowth
[41], similar to the phenotypes caused by loss of hpo, sav,
or wts.
Loss of wts or sav results in an increase in the expression
of the cell-cycle regulator cyclin E and the cell death inhibitor
Diap1 [39] at the transcriptional level [40], suggesting an
involvement of a transcriptional regulator acting down-
stream of the Hippo pathway. By yeast two-hybrid screening
using Wts as bait, the transcription co-activator Yorkie (Yki)
was identified as a major downstream target of Hippo
signaling [43]. Overexpression of yki phenocopies the loss
of Hippo pathway components and rescues the phenotypes
of Hippo pathway activation. Biochemical studies indicate
that Wts directly phosphorylates Yki at serine 168, creating
a binding site for 14-3-3 proteins, which promote cyto-
plasmic translocation of Yki [44]. Hence, the Hippo pathway
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to directly phosphorylate and activate the complex formed
by Wts and Sav. In turn, Wts phosphorylates and inactivates
the Yki transcription co-activator.
The core components of the Drosophila Hippo pathway
are highly conserved in mammals as Mst1/2 (ortholog of
Hpo), Sav, Lats1/2 (ortholog of Wts), and Mob1 (ortholog of
Mats) (Figure 2). The key downstream effectors of the
mammalian Hippo pathway are the Yes-associated protein
(Yap) and its paralog TAZ, which function as transcription
co-activators. Biochemical studies in the mammalian Hippo
pathway similarly establish a kinase cascade whereby
Mst1/2 interacts with Sav to phosphorylate and activate
the Lats1/2–Mob1 complex (reviewed in [45]). Moreover,
Lats1/2 phosphorylates Yap and Taz, resulting in their cyto-
plasmic sequestration and inactivation [44,46,47]. Consis-
tent with Drosophila studies, mutations of the components
of the mammalian Hippo pathway generate tissue over-
growth phenotypes. For instance, loss of both Mst1 and
Mst2 results in liver expansion that leads to hepatocellular
carcinoma [48]. Transgenic mouse studies also show that
activation of Yap in the liver promotes liver growth in an
inducible and reversible manner [44,46]. Remarkably,
expression of Yap, Lats1, Mst2, and Mob1 can rescue the
phenotypes of their corresponding Drosophila mutants
in vivo, highlighting a conserved role of the Hippo pathway
in organ size control.
Upstream Regulators
Acting upstream of the Hippo pathway are two FERM-
domain-containing cytoskeleton binding proteins, Merlin
(Mer) and Expanded (Ex). A FERM-domain-binding region
is present in Sav [49], suggesting a likely direct interaction
between Mer/Ex and Sav. In support of this, Ex has been
shown to co-immunoprecipitate with Hpo and Sav [49].
Loss of both Mer and Ex mimics some of the phenotypes
of Hippo pathway mutations, such as extra interommatidial
cells [50]. However, loss of either Mer or Ex only weakly
resembles the extra interommatidial phenotype, indicating
that Mer and Ex likely have independent contributions to
overgrowth induced by the Hippo pathway. Consistently,
Mer mutant clones exhibit defective apoptosis while Ex
mutant clones show impaired cell-cycle exit [51].
Inmammals the homolog ofMer is the neurofibromatosis 2
(NF2) gene, mutations of which cause an autosomal domi-
nant disorder characterized by the development of benign
tumors, such as schwannomas [52,53]. NF2 has been
shown to function antagonistically with Yap to regulate
liver development. Yap inactivation results in loss of
hepatocytes and biliary epithelial cells, whereas NF2 inacti-
vation leads to hepatocellular carcinoma and bile duct ha-
martoma [54]. Remarkably, the phenotypes induced by
NF2 deficiency are suppressed by heterozygous deletion of
Yap, thus establishing Yap as a major effector of NF2 in
growth regulation.
Loss of a Mer/Ex-interacting protein, Kibra, leads to
similar phenotypes as Hippo pathway mutations [49,55,56].
Epistatic analysis reveals that Kibra acts upstream of
Hpo and Sav and that overexpression of Kibra results in
increased phosphorylation of Wts and Yki [55,56]. Kibra
has been shown to function together with Mer and Ex in
a protein complex that localizes to the apical domain of
epithelial cells, and this protein complex regulates the Hippo
kinase cascade via direct binding to Hpo and Sav [49],suggesting the involvement of multiple protein–protein inter-
actions in this regulation.
Recent findings have provided additional insight into the
regulation of the Hippo pathway by Ex. A search for Ex-
binding proteins using affinity chromatography and mass
spectrometry identified Yki as a major Ex-binding protein in
Drosophila S2 cells [57]. This interaction, mediated by the
WW domain in Yki and the PPxY motif in Ex, results in the
nuclear export of Yki independently of Yki S168 phosphory-
lation, which is critical for 14-3-3 binding. Thus, Ex regulates
Yki via the core Hippo pathway components or via a direct
interaction.
Another upstream regulator of theHippopathway is the Fat
protocadherin, a cell surfacemolecule withmultiple cadherin
repeats [58–62]. Fat mutants exhibit a mild overgrowth
phenotype similar to that of Ex mutants. Fat is proposed
to activate the Hippo pathway by regulating the protein
level and apical membrane localization of Ex [58,60–62].
The activity of Fat is enhanced upon binding to the protocad-
herin Dachsous (Ds) [63]. Fat is regulated by several other
proteins, including the casein kinase Discs overgrown
(Dco), the Golgi-resident kinase Four-joined (Fj), and the
Fat/Ds-interacting protein Lowfat (Lft) [64–67], though the
functional significance of these interactions remains to be
investigated. Most recently, the Ste20-like kinase Tao-1 has
been reported to regulate the Hippo pathway to control
tissue growth [68]. Tao-1 activates the Hippo signaling
through direct phosphorylation of Hpo/Mst [69], providing
mechanistic insight into Hippo pathway activation.
Loss of apico-basal polarity is one of the crucial factors
that drives epithelial tumor progression. Recent studies
have suggested that proteins involved in cell polarity
play important roles in the regulation of the Hippo pathway.
These cell polarity determinants include the Scribble–Discs
large–Lethal giant larvae (Scrib–Dlg–Lgl) protein complex,
the atypical protein kinase C (aPKC), and Crumbs (Crb)
[64–67]. InDrosophila, depletion of lgl in eye epithelial tissue,
where polarity is maintained, results in Yki hyperactivation
and, consequently, hyperproliferation and diminished
apoptosis [65]. Further, lgl depletion or aPKC overexpres-
sion leads to mislocalization of hpo. In contrast, Crb overex-
pression leads to mislocalization of Ex away from the apical
cortex [66,67]. Together, these observations implicate a role
for cell polarity determinants in the regulation of tissue
growth via the Hippo pathway.
a-Catenin, a component of the adherens junction, has
recently been identified as a Yap-interacting protein that
regulates Yap localization and activity [70,71]. It binds Yap
inhigh-density humankeratinocytes, and isacritical determi-
nant of Yap nuclear activity. a-Catenin, 14-3-3 protein, and
phosphorylated Yap can form a complex in the cytoplasm
and disruption of this complex by loss of a-catenin results
in Yap1 dephosphorylation by protein phosphatase 2A
(PP2A) and subsequent nuclear translocation of Yap [71].
Interestingly, a-catenin does not affect the activation status
of Mst1/2 and Lats1/2. Moreover, Yap1 is non-responsive
to Mst1/2 and Lats1/2 depletion in epidermal cells, raising
the intriguing question of the identity of the kinase that phos-
phorylates Yap in these cells. E-cadherin has also been
shown to regulate Yap localization via catenins and the
canonical Hippo pathway [72]. Moreover, Yap has been re-
ported to interact with and be regulated by the tight junction
protein angiomotin [73]. These findings suggest potential
mechanisms for cell-contact-induced Yap inactivation.
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As a transcription co-activator, Yki does not possess a DNA-
binding domain and must interact with transcription factors
to stimulate gene expression. One transcription factor that
interacts with Yki is Scalloped (Sd), a critical regulator of
proliferation and survival of wing imaginal disc cells [74].
On the other hand, Sd is largely dispensable for the normal
growth of imaginal discs, a function for which Yki is critical,
thus suggesting that other DNA-binding transcription factors
regulate gene expression in response to basal levels of Yki.
Transcription factors that interact with Yki and regulate Yki
target gene expression have recently been reported,
including Homothorax (Hth) and Smad proteins [75,76].
InDrosophila theYki target genescyclin EandDiap1donot
account for the overgrowth phenotype inducedbyYki activa-
tion because cyclin E overexpression combined with inhibi-
tion of apoptosis does not result in the tissue overgrowth
that is characteristic of Hpo inactivation or Yki activation
[77]. A search for additional targets of Yki identified the
bantam microRNA (miRNA) as a critical biological target of
Yki. Two independent studies provide evidence to establish
that bantam is an important transcriptional target of Yki.
Bantam expression is increased by Yki overexpression, and
lossof bantampartially suppressesYki-inducedoverprolifer-
ation, while bantam overexpression partially rescues the
growth defects caused by yki mutants [78,79]. The fact that
bantam only partially rescues these defects is probably
due to the contribution of other targets, such as cyclin E
and Diap1. Consistently, simultaneous overexpression of
bantam, cyclin E, and Diap1 results in synergetic tissue over-
growth [78].Hth,which is important for cell survival andprolif-
eration anterior to the morphogenetic furrow in the eye
imaginal disc, mediates the induction of bantam expression
by yki [75]. It should be noted that there is no mammalian
homologue of the bantam miRNA. It remains to be investi-
gatedwhether Yapalso regulates amiRNAand, if so,whether
the human homologue of Hthmediates this function.
In mammals, the TEAD1–4 transcription factors have been
shown to interact with and mediate Yap-dependent gene
expression [80]. The connective tissue growth factor
(CTGF) has also been identified as a direct target of Yap/
TEADs. CTGF plays an important role in Yap-induced prolif-
eration and anchorage-independent growth [80]. However,
CTGFalonedoesnot account for theovergrowth phenotypes
induced by Yap, indicating the existence of additional key
targets of Yap in organ size regulation. Another transcrip-
tional target of Yap is amphiregulin (AREG), a ligand for the
epidermal growth factor receptor (EGFR). AREG induction
has been shown to contribute to Yap-mediated cell prolifera-
tion and knockdown of AREG abrogates the effects of Yap
overexpression [81]. Yap is also known to induce other
genes, including survivin and cyclin D1, that may contribute
to cell survival and proliferation [44].
Competition between different cell populations within
a growing organ is proposed as a mechanism for organ
size control. Studies have linked the Hippo pathway to cell
competition by identifying dMyc, a potent inducer of ribo-
some biogenesis and cell growth, as a transcriptional target
of Yki–Sd [24,25]. Interestingly, Yap also induces Myc
expression in transgenic mouse liver, although the mecha-
nism has not been reported [44]. In Drosophila local expres-
sion of dMyc induces cell competition and leads to death of
nearbywild-type cells in developingwings [16]. Consistently,
the Hippo pathway is implicated to play a role in cellcompetition and transcriptional induction of dMyc by Yki is
required for the competitive behavior of yki-expressing cells.
This finding is particularly important because it reveals a Yki
target gene that is directly involved in cell growth.
The Hippo Pathway in Organ Size Control
A distinctive phenotype of Hippo pathway mutations is the
dramatic overgrowth in the imaginal discs and in adult
organs (reviewed in [82–84]). The adult heads of flies with
Hippo pathway mutations appear larger compared with
other structures, and the mutant cells proliferate faster to
outcompete the normal wild-type cells. When compared
with wild-type cells, the Hippo pathway mutants exhibit
a dramatic increase in the numbers of interommatidial cells.
Moreover, these mutant cells fail to stop proliferating even
when imaginal tissues have reached their normal size, and
are resistant to apoptosis. The effects of Hippo pathway
mutants are observed in other structures, such as the wings,
legs, and thorax [39,85,86], suggesting that the Hippo
pathway is ubiquitously required for organ size regulation.
In mammals, activation of Yap in the liver promotes liver
growth in an inducible and reversible manner [44,46]. Loss
of both Mst1 and Mst2 and ablation of Mer or Sav in mice
also result in liver expansion [48,54,87–89]. Remarkably,
loss of one or both copies of Yap suppresses liver enlarge-
ment induced byMer deficiency [54]. Most of the overgrowth
phenotypes of Hippo pathway mutations are characterized
by increased proliferation and diminished apoptosis. This
role of the Hippo pathway in coordinating proliferation and
apoptosis is crucial during regeneration. In mice, biliary
ductal epithelial cells make a significant contribution to liver
regeneration after injury. Interestingly, a tissue-specific
knockout of Yap in the mouse liver causes a defect in bile
duct development [54]. Yap expression is also induced
during intestinal damage, and loss of Yap severely impairs
intestinal regeneration induced by dextran sodium sulfate
[90], highlighting an important function of Yap in growth
control and regeneration.
Proliferation of tissue-specific stem cells is tightly regu-
lated during development and regeneration to produce
organs of predetermined size. Accumulating evidence
supports a role for the Hippo pathway in regulating stem/
progenitor cell self-renewal and expansion. Yap activation
is observed in induced pluripotent (iPS) cells and knockdown
of Yap in mouse embryonic stem (ES) cells leads to loss of
pluripotency [91]. In contrast, Yap is inactivated in differenti-
atedmouse ES cells and ectopic expression of Yap prevents
mouse ES cell differentiation [91]. In the intestine where
endogenous Yap expression is restricted to the progenitor/
stem cell compartment, activation of Yap leads to expansion
of multipotent undifferentiated progenitor cells and these
progenitor cells differentiate when Yap expression ceases
[46]. These findings establish a function for Yap in inhibiting
progenitor/stem cell differentiation.
A recent study also highlights a critical role of Yap in the
regulation of epidermal stem cell proliferation and skin
expansion. In a transgenic mouse model, activation of Yap
in the skin causes epidermal thickening, characterized
by expansion of basal epidermal progenitor cells, and leads
to formation of squamous cell carcinoma-like tumors [71].
In contrast, knockout of Yap fails to expand basal epidermal
progenitor cells. The hyperplasia in the skin inducedbyYap is
mediated by interaction with TEAD transcription factors.
Consistently, knock-in of a Yap mutant defective in TEAD
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epidermal basal cells and failure of skin expansion. The
important function of the Hippo pathway in progenitor cell
expansion is also demonstrated by studies on liver-specific
NF2 deletion, as well as on Mst1/2 and Sav [87,89,92]. Most
recently, Taz has been suggested to play a crucial role in
cancer stem cell function. Taz activity, which correlates
with metastasis, is required to sustain self-renewal and
tumor-initiating properties of breast cancer cells [93].
The Hippo pathway has also been suggested to promote
cell competition, which influences organ growth. Cell
competition suggests that the properties of individual cells
are monitored during development and that variant clones
of progenitor cells can be favored or eliminated accordingly.
It has been reported that cells carrying different doses of
myc exhibit different behaviors [16]. Studies in Drosophila
show that hypomorphic myc mutants, although viable, are
outcompeted by wild-type cells in mosaics [28]. Recently,
dMyc has been identified as a transcriptional target and
mediator of Yki-induced cell competition [24,25]. Interest-
ingly, dMyc in turn represses the expression of yki such
that high levels of dMyc repress yki expression through tran-
scriptional and posttranscriptional mechanisms [25]. This
functional coordination of Yki and dMyc activities may serve
as an important mechanism of organ size control.
The TOR Pathway
An Overview
Rapamycin is an immunosuppressant capable of initiating
cell-cycle arrest in eukaryotic cells. The TOR kinase, muta-
tions of which relieve the growth-suppressive effects of ra-
pamycin, was first identified in yeast [94,95]. Rapamycin
requires binding to a cellular cofactor, FK506 binding protein
12kDa (FKBP12), which is capable of directly binding to TOR
causing potent inhibition of TOR activity [96]. Functionally,
the TOR kinase acts as a central signaling hub, adjusting
cellular metabolic output to match growth factor signaling
as well as energy and nutrient availability. Hyperactivation
of the TOR pathway results in increased cell growth and
can cause some cells to enter cell cycle [97–99].
TOR is a large atypical serine-threonine protein kinase,
which forms two complexes — TORC1 and TORC2 — in
yeast and mammalian cells. Rapamycin specifically inhibits
TORC1, whereas the TORC2 complex is resistant to short-
term rapamycin treatment [100]. The mammalian TORC1
complex consists of mTOR, regulatory associated protein
of mTOR (Raptor), proline rich AKT substrate 40kDa
(PRAS40), mammalian lethal with Sec-13 protein 8 (mLST8
also known as GbL), and DEP-domain TOR-binding protein
(DEPTOR) [101–105]. The Raptor subunit is essential for
TORC1 activity and promotes the formation of the TORC1
complex and substrate binding [106–108]. PRAS40 binding
to TORC1 in vitro inhibits TOR activation, and growth factor
depletion represses TORC1 activity in part through PRAS40
[109,110]. mLST8 binds to mTOR and may be involved in the
activation of mTOR in response to amino acids [107].
DEPTOR is capable of inhibiting both TORC1 and TORC2,
and its degradation is promoted by TORC1 and TORC2 [105].
TORC2 shares common subunits with TORC1, including
mTOR, DEPTOR, and mLST8. However, several unique
TORC2 complex members have been described, including
rapamycin-insensitive companion of mTOR (Rictor), Sin1,
and protein binding Rictor (Protor) [105,111–114]. The
binding of Rictor and Raptor to mTOR are exclusive to theTORC2 and TORC1 complexes, respectively. Protor associ-
ates with TORC2 through direct binding to Rictor. However,
the function of Protor is elusive as it is not required for
TORC2 assembly or activity [113]. Sin1 has been described
to promote Rictor–mTOR interaction and regulate the
substrate specificity of TORC2 [115].
Themajority of biological functions attributed tomTOR are
a result of TORC1 activity due to the availability of rapamycin
as a TORC1-specific inhibitor. TORC1 plays a central role in
the regulation of cell growth by stimulating ribosome biogen-
esis and protein translation. TORC1 also plays an important
function in autophagy, a catabolic process involving degra-
dation of cellular components that is required to maintain
essential cellular functions under periods of nutrient depriva-
tion. Evidence suggests that TORC1 inhibits autophagic
machinery through regulation of the mammalian ortholog of
yeast ATG1 (ULK1/2), a serine threonine kinase that plays
a key role in autophagy initiation [116–118]. By inhibiting
ULK1, TORC1 suppresses autophagic degradation, there-
fore maintaining cell size.
Upstream Regulators
Upstream regulators of TORC1 signaling include growth
factors, energy levels, nutrients, and oxygen (Figure 3).
Collectively, these cellular cues are integrated by TORC1 to
balance cellular energy consumption (ribosome biogenesis
and translation) and cellular energy production (autophagic
production of metabolites). Most of the signaling events,
with the exception of growth factor signaling, are selective
to TORC1 but do not affect TORC2.
The PI3K–AKT pathway is a key upstream activator of
TORC1. Activation of AKT by PI3K promotes TORC1 activity
by phosphorylating the tuberous sclerosis complex (TSC)
protein TSC2. TSC is a target of AKT and is a potent
repressor of TORC1 kinase activity in Drosophila and
mammals [99,119–121]. The TSC1–TSC2 complex functions
as a GTPase-activating protein (GAP) for Rheb, a small
GTPase that acts as a potent activator of TORC1 [122–124].
AKT activation also promotes TORC1 activity by phosphory-
lating PRAS40, relieving its inhibitory effect on TORC1 kinase
activity [121,125,126].
Amino acids are required for cell growth and are potent
inducers of TORC1 signaling. Evidence for the mechanistic
link between TORC1 activity and amino-acid sufficiency
comes from recent studies that identified and characterized
the Rag GTPase pathway [127,128]. The Rag family is part
of the Ras family of GTPases and consists of four family
members (A, B, C, D). Activation of TORC1 by Rag GTPases
requires the activity of Rheb, indicating that Rag proteins
act in the same pathway as Rheb in the activation of TORC1
by amino acids. Other proteins have been reported to have
a role in the regulation of TORC1activity in response to amino
acids, including VPS34 lipid kinase and the Ste20-related
kinase MAP4K3 [129–133]. Interestingly, VPS34 is involved
in endocytic vesicle transport and may affect the lysosomal
activation of TORC1 by Rags. Additional studies are required
to clarify the role of these genes in TORC1 activation.
The AMP-activated protein kinase (AMPK) plays an impor-
tant role in cellular energy homeostasis. Under conditions
of energy depletion, AMP levels are elevated and the corre-
sponding response is activation of AMPK, which reduces
energy-intensive processes, such as ribogenesis and trans-
lation [134]. AMPK inhibits the TORC1 complex by increasing
TSC1–TSC2 complex activity through direct phosphorylation
AKT 
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Figure 3. The TOR pathway.
Genes that activate or inhibit TOR are labeled
in blue and red boxes, respectively. Down-
stream targets of TOR are labeled in green
boxes. See text for details.
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R374of TSC2, aswell as inhibiting substrate recruitment to TORC1
via phosphorylation of Raptor [135,136]. Moreover, AMPK-
mediated phosphorylation of TSC2 enhances the activation
of TSC2 by glycogen synthase kinase 3 (GSK3) [137].
Downstream Targets
The two best characterized targets of TORC1 are the eIF4E-
binding protein (4E-BP) and S6K, through which TORC1
regulates the assembly of the translation machinery on
a subset of mRNA transcripts [138]. When conditions for
growth are unfavorable, TORC1-mediated inhibition of
4E-BP is relieved, allowing 4E-BP to inhibit the pro-transla-
tion factor eIF4E and resulting in a decrease in protein trans-
lation [138,139]. TORC1 also targets S6K, a kinase that
targets multiple substrates required for the progression of
the ribosome towards the start codon of mRNA [138–140].
Importantly, TORC1 has also been shown to regulate ribo-
some biogenesis and tRNA production through increases
in phosphorylation of transcriptional regulators of these
processes [141,142]. TORC1 also regulates cellular catabolic
process, such as inhibition of autophagy, by phosphory-
lating and inactivating the autophagy-initiating kinase
ULK1 [143].
The TOR Pathway in Organ Size Control
Cell division is influenced by cell size. The ability of TORC1 to
regulate cell size has been best described in Drosophila
models. Disruption of dTORC1 activity results in a reduction
of both cell size and cell proliferation, closely mimicking
the effects of sustained nutrient deprivation [27]. Disruption
of S6K or 4E-BP also results in decreased cell size
[27,99,144,145]. Regulation of growth by TORC1 by cuesfrom energy-sensing organs is also
demonstrated in the Drosophila
model. Deletion of slimfast, an amino-
acid transporter, in the fat body of
Drosophila results in a TORC1-depen-
dent reduction of cell and organism
size [146]. Similarly, rapamycin treat-
ment reduces the size of mammalian
cells in culture [140].
Given the central role of TORC1 in
regulating growth, it is not surprising
that disruption or activation of this
pathway is linked to changes in
organ size. For instance, deletion of
dTOR leads to reduction in growth in
larval development [27]. Moreover,
dTOR deletion curbs the overgrowth
phenotype caused byPTEN loss. Addi-
tionally, TSC1 or TSC2 deletion in
Drosophila results in overgrowth of
organs and body size [147]. Interest-
ingly, lethality in flies harboring a
loss-of-function mutation in the IGF-1
receptor can be rescued by deletionof a single TSC1 allele. Genetic studies have revealed that
translational regulation by TORC1 is a key contributor to
the changes observed in organ and tissue size. Deletion of
the TORC1 target S6K decreases body size in Drosophila
as a result of decreased cell size rather than decreased cell
number [26]. This is in contrast to the dRheb deletion, which
reduces both cell size and number, suggesting that TORC1
regulates organ size in a S6K- or translation-independent
manner [148,149]. In mice, S6K1 deletion leads to a small
body phenotype during embryogenesis that is partially
compensated for by increases in S6K2 activity, indicating
the conserved role of translational control by TORC1 in the
regulation of cell and tissue size [150].
Disruption of insulin signaling to AKT results in retardation
of organ and organism size in both Drosophila and mamma-
lian models [151,152]. For example, mutation of IRS-1 in
mice or Chico in Drosophila results in smaller body and
organ size, highlighting the conservation of insulin signaling
in the regulation and promotion of organ growth [153].
Conversely, promotion of insulin–AKT signaling by inactiva-
tion of PTEN results in overgrowth of organs and body
size due to increased proliferation and cell size. The down-
stream AKT targets TORC1 and FoxO have both been
implicated in the regulation of organ size and tissue
overgrowth [27,154].
Interplay Between the Hippo and TOR Pathways
The roles of Hippo and TOR in organ size regulation are well
established by their respective functions in controlling cell
number and cell size. Emerging evidence suggests that
components of the Hippo pathway play an important role
in the regulation of TOR activity. For instance, deletion of
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R375NF2, themammalian homologue ofMer, results in the activa-
tion of mTORC1 that is associated with meningioma and
schwannoma growth [155,156]. Analysis of a panel of malig-
nant mesothelioma cell lines further reveals a strong correla-
tion between loss ofMer and activation of mTORC1 [156]. A
recent study also indicates that Yap regulates IGF-1, a known
upstream activator of the mTOR pathway, to promote cardi-
omyocyte proliferation and embryonic heart size [157]. Simi-
larly, loss of Mst1 or Mst2 leads to mTORC1 activation [48]
and Mst1 affects mTORC2 downstream signaling [158].
Mst1 is suggested to promote oxidative-stress-induced
cell death in primary mammalian neurons by directly acti-
vating Foxo transcription factors, substrates of AKT. Mst1
is shown to phosphorylate Foxo1 proteins at a conserved
site within the forkhead domain that disrupts their interaction
with 14-3-3 proteins, promotes Foxo nuclear translocation,
and induces cell death in neurons [159].
Myc, a transcription factor important for cellular growth,
has been identified as a transcriptional target of Yki. Impor-
tantly, Yki-induced upregulation of myc is required for the
supercompetitive behavior of yki-expressing cells [24,25].
Among the transcriptional targets of Myc are translation initi-
ation factors, which lie downstream of mTORC1 signaling
[29,30]. Myc has also been shown to directly affect the tran-
scription of TSC2 by binding to the TSC2 promoter [160].
These studies suggest an essential function of Yki in
promoting cell growth via dMyc. It remains to be investigated
whether Yap is directly involved in the regulation of mTOR
activity.
Cell-cycle progression affects the rate of organ growth.
Central to cell-cycle progression is the Retinoblastoma
protein (pRB), which exerts its function as a tumor sup-
pressor by promoting cell-cycle exit through control of the
activity of the family of E2F transcription factors [161,162].
Overexpression of E2Fs results in cell-cycle advancement
fromG1 to Sphase, and expression of pRBblocks this effect,
providing a switch mechanism for the inhibition of cell prolif-
eration [163]. A recent study has demonstrated that Lats2
cooperates with pRB to promote silencing of E2F target
genes, resulting in cell cycle arrest [164]. The Lats2 effect
does not seem to involve Yapbut a novel substrate, DYRK1A.
However, in Drosophila Yki itself plays a role in the induction
of pRB phenotypes. The Yki–Sd complex has been reported
to synergize with and require dE2F to induce a specific tran-
scriptional program that is necessary tobypass the cell-cycle
exit [165]. Yki–Sd and dE2F bind directly to the promoters of
the Yki–Sd–dE2F shared target genes and activate the
expression of these genes in a cooperative manner. Interest-
ingly, E2F has been reported to regulate TORC1 by a tran-
scriptional mechanism [166]. These studies imply that the
TOR pathway is a downstream target of Hippo signaling.
Conclusions and Perspectives
As yet, there is no concrete link between the Hippo and TOR
pathways that has been defined mechanistically. Hippo and
TOR are well-established regulators of organ size, and their
prominent roles in organ size control are highlighted by
several studies demonstrating that genetic mutation in these
pathways is sufficient to alter organ or body size through
increases in cell number, cell size, or both. However, the indi-
vidual roles of TOR and Hippo in organ size control still need
to be precisely defined. In the case of TOR, targets beyond
S6K, 4EBP1, and ULK1 in cell size control have not been
extensively explored. TOR is a key integrator of multipleupstream signals and a regulator of diverse functions,
including metabolism and aging. Given that translational
control via S6K1 and 4E-BP1 only partially accounts for the
role of TOR in maintaining whole-body metabolism, addi-
tional TOR targets must exist. The activity of autophagy
certainly contributes to overall cellular contents and hence
cell size. As for the Hippo pathway, several transcription
factors interacting with Yap/Taz/Yki have been reported
but the functional significance of most of these interactions
has not been extensively studied. In mammals, Yap and
Taz are known to induce genes involved in cell proliferation,
including BIRC5 and cyclin D1, but it has not been investi-
gatedwhether these are critical mediators of Yap-dependent
functions. Moreover, it is likely that the Lats kinase has
additional substrates that may play a role in organ size
control.
The upstream regulators of the TORpathway arewell char-
acterized, though in the case of Hippo the upstream signals
are missing. Cell contact has been implicated to activate the
Hippo pathway, but the key mediators of this regulation are
unknown. Additionally, genes that are involved in cell
contact, cell adhesion, and cell polarity have been described
to affect Hippo pathway activity. However, how and under
what conditions these genes activate the Hippo pathway
are unclear. As cytoskeletal-associated proteins, the Hippo
pathway components Mer and Ex might potentially be
involved in relaying mechanical or morphological signals,
or signals from as yet unidentified transmembrane receptors
to activate the Hippo pathway. In addition, the cytoskeletal
pathway involving the Rho GTPase has recently been shown
to affect Yap activity, and Lats and Mob1 are suggested to
interact with cytoskeletal proteins. However, the specific
role of the cytoskeleton in the regulation of the Hippo
pathway remains to be elucidated.
Existing evidence has established critical roles of the
Hippo and TOR pathways in organ size regulation. Future
studies should aim to delineate the mechanistic interactions
between the two pathways and upstream signals for the
Hippo pathway to establish a better understanding of organ
size determination.
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